title: [Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants].
abstract: The introduction of new direct oral anticoagulants has changed the treatment of nonvalvular atrial fibrillation. However, these changes are not yet fully reflected in current guidelines.This consensus statement, endorsed by six Austrian medical societies, provides guidance to current prophylactic approaches of thromboembolic events in nonvalvular atrial fibrillation on the basis of current evidence and published guidelines. Furthermore, some special subjects are treated, like changes in laboratory parameters and their interpretation under treatment with direct oral anticoagulants, treatment of bleedings, approach to operations, cardioversion and ablation, and specific neurological aspects. For a CHA2DS2-VASc-Score of ≥ 2, anticoagulation is recommended with a high level of evidence (1A). At the end of the consensus statement, recommendations for a number of specific patient subgroups can be found, in order to help treating physicians to arrive at appropriate therapeutic decisions.
authors.affiliation: Klin. Abt. für Hämatologie u. Hämostaseologie, Univ.-Klin. f. Innere Medizin I, MedUni Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich, ingrid.pabinger@meduniwien.ac.at.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Pabinger
authors.forename: Wilfried
authors.initials: W
authors.lastname: Lang
authors.forename: Franz Xaver
authors.initials: FX
authors.lastname: Roithinger
authors.forename: Franz
authors.initials: F
authors.lastname: Weidinger
authors.forename: Sabine
authors.initials: S
authors.lastname: Eichinger-Hasenauer
authors.forename: Reinhold
authors.initials: R
authors.lastname: Glehr
authors.forename: Walter-Michael
authors.initials: WM
authors.lastname: Halbmayer
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Haring
authors.forename: Bernd
authors.initials: B
authors.lastname: Jilma
authors.forename: Hans Christian
authors.initials: HC
authors.lastname: Korninger
authors.forename: Sibylle
authors.initials: S
authors.lastname: Kozek-Langenecker
authors.forename: Paul
authors.initials: P
authors.lastname: Kyrle
authors.forename: Herbert
authors.initials: H
authors.lastname: Watzke
authors.forename: Ansgar
authors.initials: A
authors.lastname: Weltermann
authors.forename: Johann
authors.initials: J
authors.lastname: Willeit
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D001317:Austria; D002309:Cardiology / Q000592:standards*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006349:Heart Valve Diseases / Q000150:complications / Q000628:therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants